Shalini Sharp

Shalini Sharp joined Mirati’s Board of Directors in March 2021. She has more than 25 years of financial and corporate strategy experience in the life sciences industry. Most recently, she was the Chief Financial Officer (CFO) at Ultragenyx where she was responsible for leading the company’s corporate finance, strategy, and information technology functions. Prior to Ultragenyx, Shalini was CFO at Agenus Inc., and before that, she worked in corporate strategy at Elan Pharmaceuticals, management consulting at McKinsey & Company, and investment banking at Goldman Sachs, in the pharmaceutical and medical device space. Shalini also serves as a board member of Neurocrine Biosciences, Precision Biosciences, Sutro Biopharma and TB Alliance. She previously served on the boards of Array BioPharma, Panacea Acquisition Corporation and Agenus. Shalini received her MBA from Harvard Business School and holds a B.A. from Harvard College.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.